NasdaqGS:DNLIBiotechs
Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News
Denali Therapeutics stock has delivered a 63.4% return over the past year. However, both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a premium rather than at a clear discount.
Over the last 12 months, a 63.4% gain has rewarded Denali Therapeutics shareholders. This raises the question of how much future upside is already reflected in the price.
Excitement around Denali Therapeutics' progress in delivering biologic...